Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

Recent & Breaking News (CSE:WBIO)

WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications

GlobeNewswire March 24, 2020

CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

PR Newswire March 23, 2020

Top Pharmaceutical Companies Racing for a Vaccine to Halt the Coronavirus

Livemoney March 19, 2020

WPD PHARMACEUTICALS' WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS

GlobeNewswire March 19, 2020

WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

GlobeNewswire March 16, 2020

WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

GlobeNewswire March 13, 2020

WPD PHARMACEUTICALS RECEIVED $800,000 REIMBURSEMENT FROM $7.4 MILLION GOVERNMENT GRANT FOR DEVELOPMENT OF GLIOBLASTOMA DRUG

GlobeNewswire March 11, 2020

WPD Pharmaceuticals Granted Key Patent Exclusively Licensed From Wake Forest University

GlobeNewswire February 24, 2020

WPD Pharmaceuticals to Conduct Clinical Trials in Pediatric Brain Tumors Through Collaboration With CNS Pharmaceuticals

GlobeNewswire February 12, 2020

WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates Bringing Total Development Funding Spent on Drugs Under License to Over USD $100 Million

GlobeNewswire February 3, 2020

WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates

GlobeNewswire January 31, 2020

WPD Pharmaceuticals Receives European Patent for Cancer Targeting Drugs

GlobeNewswire January 29, 2020

Westcot Ventures Corp. Announces Name Change to "WPD Pharmaceuticals Inc."

GlobeNewswire January 14, 2020

WPD Pharmaceuticals Provides 2019 Corporate Year End Review

GlobeNewswire January 8, 2020

Westcot Ventures Corp. Announces Closing of Transaction of WPD Pharmaceuticals Sp. Z.o.o.

GlobeNewswire December 24, 2019

IIROC Trading Halt - SPW.H

Canada NewsWire June 16, 2015

IIROC Trade Halt - Sparrow Ventures Corp.

Newsfile June 16, 2015